Drugs / BC222insulin lispro
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03262116 | Mar → Jul 2019 | type 1 diabetes mellitus | Massachusetts General Hospital | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06153329 Comparator | Jun 2021 → Jun 2022 | — | Tonghua Dongbao Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BC222insulin lispro | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06153329 ↗ |
| Modality | Protein / enzyme biologic | “rapid acting insulin analog” NCT03262116 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT06153329 ↗ |